Mirogabalin

Drug Profile

Mirogabalin

Alternative Names: DS 5565

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Acetic acids; Aminobutyric acids; Analgesics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuropathic pain; Pain; Postherpetic neuralgia
  • Phase I Kidney disorders

Most Recent Events

  • 31 Aug 2017 Top-line efficacy and adverse events data from a phase III trial in Neuropathic pain released by Daiichi Sankyo
  • 30 Aug 2017 Daiichi plans a phase I trial in Healthy volunteers in China (JapicCTI-173680)
  • 06 Jul 2017 Daiichi Sankyo completes a phase III trial in Pain in USA, South Africa, Hungary, Czech Republic, Spain, Poland, Romania, and Bulgaria (PO) (NCT02496884)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top